Evidence map›Paper›PMID 34359987›Full record

ReviewCells2021

Interplay between Neutrophils, NETs and T-Cells in SARS-CoV-2 Infection-A Missing Piece of the Puzzle in the COVID-19 Pathogenesis?

Paulina Niedźwiedzka-Rystwej, Ewelina Grywalska, Rafał Hrynkiewicz, Dominika Bębnowska, Mikołaj Wołącewicz, Adam Majchrzak, Miłosz Parczewski

Abstract readReview
In one paragraph

Review in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Tackling COVID-19 Using Antiviral Nanocoating's-Recent Progress and Future Challenges.Particle & particle systems characterization : measurement and description of particle properties and behavior in powders and other disperse systems · 2023
    Review
  3. Article
  4. Review
  5. An inhibitor of leukotriene-AProceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Paulina Niedźwiedzka-RystwejInstitute of Biology, University of Szczecin, 71-412 Szczecin, Poland.ORCID 0000-0003-4065-3842
Ewelina GrywalskaDepartment of Clinical Immunology and Immunotherapy, Medical University of Lublin, 20-093 Lublin, Poland.ORCID 0000-0002-0451-4741
Rafał HrynkiewiczInstitute of Biology, University of Szczecin, 71-412 Szczecin, Poland.ORCID 0000-0002-0688-6928
Dominika BębnowskaInstitute of Biology, University of Szczecin, 71-412 Szczecin, Poland.ORCID 0000-0003-3689-2381
Mikołaj WołącewiczDepartment of Environmental Microbiology and Biotechnology, University of Warsaw, 02-096 Warsaw, Poland.ORCID 0000-0002-8185-7078
Adam MajchrzakDepartment of Pediatric Infectious Diseases, Independent Public Regional Hospital in Szczecin, 71-455 Szczecin, Poland.ORCID 0000-0002-8874-8026
Miłosz ParczewskiDepartment of Infectious, Tropical Diseases and Immune Deficiency, Pomeranian Medical University in Szczecin, 71-455 Szczecin, Poland.ORCID 0000-0003-1869-1084

Funding

The National Centre For Research and Development Agreement No. SZPITALE-JEDNOIMIENNE/27/2020, November 20th, 2020
6 · The paper itself

Abstract

Since the end of 2019, a new, dangerous virus has caused the deaths of more than 3 million people. Efforts to fight the disease remain multifaceted and include prophylactic strategies (vaccines), the development of antiviral drugs targeting replication, and the mitigation of the damage associated with exacerbated immune responses (e.g., interleukin-6-receptor inhibitors). However, numerous uncertainties remain, making it difficult to lower the mortality rate, especially among critically ill patients. While looking for a new means of understanding the pathomechanisms of the disease, we asked a question-is our immunity key to resolving these uncertainties? In this review, we attempt to answer this question, and summarize, interpret, and discuss the available knowledge concerning the interplay between neutrophils, neutrophil extracellular traps (NETs), and T-cells in COVID-19. These are considered to be the first line of defense against pathogens and, thus, we chose to emphasize their role in SARS-CoV-2 infection. Although immunologic alterations are the subject of constant research, they are poorly understood and often underestimated. This review provides background information for the expansion of research on the novel, immunity-oriented approach to diagnostic and treatment possibilities.

Indexed as

AnimalsCOVID-19Extracellular TrapsHumansImmunity, InnateNeutrophilsSARS-CoV-2T-LymphocytesCOVID-19immunityNETneutrophilSARS-CoV-2T cells

Identifiers

PMID34359987
PMCPMC8304299

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.